Project
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention (ARISE-Study)
Automatically Closed · 2015 until 2017
Flügel Dominique, Zieglgänsberger Dominik, Müller Anna
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2015
End Date
2017
Financing
Industry
Study Design
Phase 3, multicenter, randomized, stratified, double-blind, placebo-controlled,
parallel-group study of subjects with episodic migraine. Approximately 540 subjects will be
randomized 1:1 to placebo or AMG 334 70 mg. The randomization will be stratified by region
(North America vs Other) and prior treatment with migraine prophylactic medication
(prior migraine prophylactic medication treatment vs no prior migraine prophylactic medication
treatment).
Keywords
episodic migraine, cgrp-receptor-antagonist
Homepage
Partner
Quintiles
Brief description/objective
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with episodic migraine